Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 132

1.

Success of HPV vaccination is now a matter of coverage.

Schiffman M, Wacholder S.

Lancet Oncol. 2012 Jan;13(1):10-2. doi: 10.1016/S1470-2045(11)70324-2. Epub 2011 Nov 8. No abstract available. Erratum in: Lancet Oncol. 2012 Jan;13(1):e1.

PMID:
22075169
2.

Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine.

Di Mario S, Basevi V, Borsari S, Balduzzi S, Magrini N.

Lancet Oncol. 2012 Feb;13(2):e50; author reply e50. doi: 10.1016/S1470-2045(12)70054-2. No abstract available.

PMID:
22300857
3.

Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.

Lehtinen M, Paavonen J, Wheeler CM, Jaisamrarn U, Garland SM, Castellsagué X, Skinner SR, Apter D, Naud P, Salmerón J, Chow SN, Kitchener H, Teixeira JC, Hedrick J, Limson G, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, De Carvalho NS, Germar MJ, Peters K, Mindel A, De Sutter P, Bosch FX, David MP, Descamps D, Struyf F, Dubin G; HPV PATRICIA Study Group.

Lancet Oncol. 2012 Jan;13(1):89-99. doi: 10.1016/S1470-2045(11)70286-8. Epub 2011 Nov 8. Erratum in: Lancet Oncol. 2012 Jan;13(1):e1.

PMID:
22075171
4.

Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.

Wheeler CM, Castellsagué X, Garland SM, Szarewski A, Paavonen J, Naud P, Salmerón J, Chow SN, Apter D, Kitchener H, Teixeira JC, Skinner SR, Jaisamrarn U, Limson G, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, Harper DM, Huh W, Hardt K, Zahaf T, Descamps D, Struyf F, Dubin G, Lehtinen M; HPV PATRICIA Study Group.

Lancet Oncol. 2012 Jan;13(1):100-10. doi: 10.1016/S1470-2045(11)70287-X. Epub 2011 Nov 8. Erratum in: Lancet Oncol. 2012 Jan;13(1):e1.

PMID:
22075170
5.

Efficacy of human papillomavirus 16 and 18 (HPV-16/18) AS04-adjuvanted vaccine against cervical infection and precancer in young women: final event-driven analysis of the randomized, double-blind PATRICIA trial.

Apter D, Wheeler CM, Paavonen J, Castellsagué X, Garland SM, Skinner SR, Naud P, Salmerón J, Chow SN, Kitchener HC, Teixeira JC, Jaisamrarn U, Limson G, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, Mindel A, de Sutter P, Hardt K, Zahaf T, Descamps D, Struyf F, Lehtinen M, Dubin G; HPV PATRICIA Study Group.

Clin Vaccine Immunol. 2015 Apr;22(4):361-73. doi: 10.1128/CVI.00591-14. Epub 2015 Feb 4.

6.

AS04-adjuvanted human papillomavirus-16/18 vaccination: recent advances in cervical cancer prevention.

Schwarz TF.

Expert Rev Vaccines. 2008 Dec;7(10):1465-73. doi: 10.1586/14760584.7.10.1465. Review.

PMID:
19053203
7.

Gynaecological cancer: HPV vaccine: is age just a number?

Stone L.

Nat Rev Urol. 2014 Nov;11(11):605. doi: 10.1038/nrurol.2014.268. Epub 2014 Sep 23. No abstract available.

PMID:
25245243
8.

Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial.

Kreimer AR, González P, Katki HA, Porras C, Schiffman M, Rodriguez AC, Solomon D, Jiménez S, Schiller JT, Lowy DR, van Doorn LJ, Struijk L, Quint W, Chen S, Wacholder S, Hildesheim A, Herrero R; CVT Vaccine Group.

Lancet Oncol. 2011 Sep;12(9):862-70. doi: 10.1016/S1470-2045(11)70213-3. Epub 2011 Aug 22. Erratum in: Lancet Oncol. 2011 Nov;12(12):1096.

9.

Human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for the prevention of cervical cancer and HPV-related diseases.

Skinner SR, Apter D, De Carvalho N, Harper DM, Konno R, Paavonen J, Romanowski B, Roteli-Martins C, Burlet N, Mihalyi A, Struyf F.

Expert Rev Vaccines. 2016;15(3):367-87. doi: 10.1586/14760584.2016.1124763. Review.

PMID:
26902666
10.

Randomized trial: immunogenicity and safety of coadministered human papillomavirus-16/18 AS04-adjuvanted vaccine and combined hepatitis A and B vaccine in girls.

Pedersen C, Breindahl M, Aggarwal N, Berglund J, Oroszlán G, Silfverdal SA, Szüts P, O'Mahony M, David MP, Dobbelaere K, Dubin G, Descamps D.

J Adolesc Health. 2012 Jan;50(1):38-46. doi: 10.1016/j.jadohealth.2011.10.009.

PMID:
22188832
11.

Cervarix®: a bivalent vaccine against HPV types 16 and 18, with cross-protection against other high-risk HPV types.

Szarewski A.

Expert Rev Vaccines. 2012 Jun;11(6):645-57. doi: 10.1586/erv.12.42.

PMID:
22873123
12.

Cervical cancer vaccination: the real meaning of cross-protection and its impact on the prevention.

De Carvalho NS.

Vaccine. 2008 Nov 25;26(50):6293-4. doi: 10.1016/j.vaccine.2008.09.001. Epub 2008 Sep 18.

PMID:
18804508
13.

Cervical cancer vaccine development.

Frazer IH.

Sex Health. 2010 Sep;7(3):230-4. doi: 10.1071/SH09132. Review.

PMID:
20719210
14.

Safety and immunogenicity of human papillomavirus-16/18 AS04-adjuvanted vaccine: a randomized trial in 10-25-year-old HIV-Seronegative African girls and young women.

Sow PS, Watson-Jones D, Kiviat N, Changalucha J, Mbaye KD, Brown J, Bousso K, Kavishe B, Andreasen A, Toure M, Kapiga S, Mayaud P, Hayes R, Lebacq M, Herazeh M, Thomas F, Descamps D.

J Infect Dis. 2013 Jun 1;207(11):1753-63. doi: 10.1093/infdis/jis619. Epub 2012 Dec 13.

15.

Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical intraepithelial neoplasia and cervical infection in young Japanese women.

Konno R, Yoshikawa H, Okutani M, Quint W, V Suryakiran P, Lin L, Struyf F.

Hum Vaccin Immunother. 2014;10(7):1781-94. doi: 10.4161/hv.28712.

16.

Who should be targeted for vaccination against anal cancer?

Harper DM, Vierthaler SL.

Lancet Oncol. 2011 Sep;12(9):828-9. doi: 10.1016/S1470-2045(11)70237-6. Epub 2011 Aug 22. No abstract available.

PMID:
21865086
18.

[Risk factors of cervical cancer and possibilities of primary prevention].

Nowakowski AM, Kotarski J.

Przegl Epidemiol. 2011;65(1):81-8. Polish.

PMID:
21735842
19.

Randomized trial of the immunogenicity and safety of the Hepatitis B vaccine given in an accelerated schedule coadministered with the human papillomavirus type 16/18 AS04-adjuvanted cervical cancer vaccine.

Leroux-Roels G, Haelterman E, Maes C, Levy J, De Boever F, Licini L, David MP, Dobbelaere K, Descamps D.

Clin Vaccine Immunol. 2011 Sep;18(9):1510-8. doi: 10.1128/CVI.00539-10. Epub 2011 Jul 6.

20.

Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study.

Romanowski B, Schwarz TF, Ferguson LM, Peters K, Dionne M, Schulze K, Ramjattan B, Hillemanns P, Catteau G, Dobbelaere K, Schuind A, Descamps D.

Hum Vaccin. 2011 Dec;7(12):1374-86. doi: 10.4161/hv.7.12.18322. Epub 2011 Dec 1.

Supplemental Content

Support Center